Slenyto is a medicine used to treat insomnia (difficulty sleeping) in: - children and adolescents (2 to 18 years old) who have autism spectrum disorder (ASD), a range of conditions that affects a person’s social interactions, and/or neurogenetic disorders (conditions caused by changes in genes that affect the functioning of the brain) associated with an abnormal production of melatonin or night awakenings, or both. Melatonin is a hormone that plays a key role in coordinating the body’s sleep-wake cycle; - children and adolescents (6 to 17 years old) who have attention-deficit hyperactivity disorder (ADHD). Slenyto is used after other measures, such as keeping to a regular sleeping routine, have not worked. The medicine contains the active substance melatonin.
Therapeutic Indication
### Therapeutic indication Slenyto is indicated for: - treatment of insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder (ASD), and / or neurogenetic disorders with aberrant diurnal melatonin secretion and /or nocturnal awakenings, where sleep hygiene measures have been insufficient. - treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.
Therapeutic Area (MeSH)
ATC Code
N05CH01
ATC Item
melatonin
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| melatonin | N/A | 褪黑素 |
EMA Name
Slenyto
Medicine Name
Slenyto
Aliases
N/ANo risk management plan link.
